UK biotech brings in $226M Series C

Apollo Therapeutics is reeling in a $226.5 million Series C round, the biotech said Wednesday.

The financing is two-pronged: It aims to advance Apollo’s clinical programs and back its drug discovery efforts, and potentially license or acquire clinical-stage candidates that meet certain criteria.

“This latest fundraising enables us to take our most advanced programs to key clinical value inflection points,” Apollo CEO Richard Mason said in a press release.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Antioxidant-rich diet could help lower risk of infertility in women, new study suggests

The study reveals that increased antioxidant consumption may protect against infertility in women, addressing oxidative stress in reproductive disorders.

October 3, 2024

Overtreatment of older men with prostate cancer raises concerns

Increasing percentages of some older U.S. men with intermediate-risk and high-risk prostate cancers are undergoing treatments that carry risks of side effects that can significantly

November 12, 2024

Scientists map the genetic landscape of drug resistance in cancers

All cancer mutations that cause drug resistance fall into one of four categories. New research has detailed each type, helping to uncover targets for drug

October 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.